Atossa Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$4.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly31.7M
Quarterly Net Loss Quarterly-9.6M
Quarterly Research and Development Expenses Quarterly4.8M
Watch Items
- EVANGELINE Phase 2 Trial Enrollment and Preliminary DataTrigger: Enrollment conclusion expected by mid-2026; preliminary data anticipated later in 2026Action: Monitor clinical trial updates and press releases for neoadjuvant (Z)-endoxifen data
- Going Concern and Cash RunwayTrigger: Cash balance of $31.7 million as of March 31, 2026, with substantial doubt about going concernAction: Track cash burn rate, ATM utilization, and potential warrant exercises from the June 2026 registered direct offering
- Regulatory Strategy and FDA Discussions for (Z)-endoxifenTrigger: FDA feedback on regulatory pathways for breast cancer risk reduction and rare pediatric diseases (DMD, McCune-Albright)Action: Evaluate regulatory milestones and potential eligibility for a Priority Review Voucher (PRV)
Research as of 19 Jun 2026